Bristol-Myers Squibb Company

56.73-0.4900-0.86%Vol 11.56M1Y Perf -19.65%
Oct 4th, 2023 16:00 DELAYED
BID56.47 ASK57.10
Open57.10 Previous Close57.22
Pre-Market- After-Market56.85
 - -  0.12 0.21%
Target Price
80.08 
Analyst Rating
Moderate Buy 2.29
Potential %
41.16 
Finscreener Ranking
     41.35
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★     45.27
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★+     55.74
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★★     44.46
Price Range Ratio 52W %
-1.60 
Earnings Rating
Sell
Market Cap118.51B 
Earnings Date
26th Oct 2023
Alpha-0.00 Standard Deviation0.06
Beta0.43 

Today's Price Range

56.3157.34

52W Range

57.1281.44

5 Year PE Ratio Range

-13.30116.80

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.43%
1 Month
-6.45%
3 Months
-12.36%
6 Months
-18.75%
1 Year
-19.65%
3 Years
-4.17%
5 Years
-9.10%
10 Years
25.76%

TickerPriceChg.Chg.%
BMY56.73-0.4900-0.86
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
Financial StrengthValueIndustryS&P 500US Markets
1.20
1.40
0.54
1.23
7.10
Leverage Ratio 3.10
ProfitabilityValueIndustryS&P 500US Markets
78.50
19.20
41.30
13.90
12.43
RevenueValueIndustryS&P 500US Markets
34.75B
16.35
25.79
20.30
DividendsValueIndustryS&P 500US Markets
3.21
2.28
10.59
11.43
Payout ratio273.00
Earnings HistoryEstimateReportedSurprise %
Q02 20231.991.75-12.06
Q01 20231.982.053.54
Q04 20221.711.826.43
Q03 20221.831.998.74
Q02 20221.791.937.82
Q01 20221.921.962.08
Q04 20211.831.830.00
Q03 20211.912.004.71
Earnings Per EndEstimateRevision %Trend
9/2023 QR1.81-9.05Negative
12/2023 QR1.80-8.63Negative
12/2023 FY7.43-7.93Negative
12/2024 FY7.85-2.12Negative
Next Report Date26th Oct 2023
Estimated EPS Next Report1.80
Estimates Count10
EPS Growth Next 5 Years %5.10
Volume Overview
Volume11.56M
Shares Outstanding2.09M
Shares Float2.09B
Trades Count91.32K
Dollar Volume654.97M
Avg. Volume10.27M
Avg. Weekly Volume9.84M
Avg. Monthly Volume10.96M
Avg. Quarterly Volume10.02M

Bristol-Myers Squibb Company (NYSE: BMY) stock closed at 56.73 per share at the end of the most recent trading day (a -0.86% change compared to the prior day closing price) with a volume of 11.56M shares and market capitalization of 118.51B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 30250 people. Bristol-Myers Squibb Company CEO is Giovanni Caforio.

The one-year performance of Bristol-Myers Squibb Company stock is -19.65%, while year-to-date (YTD) performance is -21.15%. BMY stock has a five-year performance of -9.1%. Its 52-week range is between 57.12 and 81.435, which gives BMY stock a 52-week price range ratio of -1.60%

Bristol-Myers Squibb Company currently has a PE ratio of 23.80, a price-to-book (PB) ratio of 4.75, a price-to-sale (PS) ratio of 4.34, a price to cashflow ratio of 11.50, a PEG ratio of 4.67, a ROA of 6.95%, a ROC of 9.97% and a ROE of 20.80%. The company’s profit margin is 12.43%, its EBITDA margin is 41.30%, and its revenue ttm is $34.75 Billion , which makes it $16.35 revenue per share.

Of the last four earnings reports from Bristol-Myers Squibb Company, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.80 for the next earnings report. Bristol-Myers Squibb Company’s next earnings report date is 26th Oct 2023.

The consensus rating of Wall Street analysts for Bristol-Myers Squibb Company is Moderate Buy (2.29), with a target price of $80.08, which is +41.16% compared to the current price. The earnings rating for Bristol-Myers Squibb Company stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bristol-Myers Squibb Company has a dividend yield of 3.21% with a dividend per share of $2.28 and a payout ratio of 273.00%.

Bristol-Myers Squibb Company has a Sell technical analysis rating based on Technical Indicators (ADX : 5.01, ATR14 : 0.89, CCI20 : -140.21, Chaikin Money Flow : -0.40, MACD : -0.92, Money Flow Index : 29.70, ROC : -3.07, RSI : 29.75, STOCH (14,3) : 2.92, STOCH RSI : 0.00, UO : 37.06, Williams %R : -97.08), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bristol-Myers Squibb Company in the last 12-months were: Adam Lenkowsky (Option Excercise at a value of $0), Ann Powell Judge (Option Excercise at a value of $0), Ann Powell Judge (Sold 11 183 shares of value $835 258 ), Boerner Christopher (Option Excercise at a value of $0), Caforio Giovanni (Option Excercise at a value of $0), Caforio Giovanni (Sold 240 000 shares of value $17 916 000 ), Christopher S. Boerner (Option Excercise at a value of $0), David V. Elkins (Option Excercise at a value of $0), Elizabeth A. Mily (Option Excercise at a value of $0), Elizabeth Mily (Option Excercise at a value of $0), Giovanni Caforio (Option Excercise at a value of $0), Giovanni Caforio (Sold 240 000 shares of value $17 916 000 ), Gregory Scott Meyers (Sold 0 shares of value $0 ), Karin Shanahan (Sold 0 shares of value $0 ), Leung Sandra (Option Excercise at a value of $0), Michelle Weese (Option Excercise at a value of $0), Powell Ann Judge (Option Excercise at a value of $0), Powell Ann Judge (Sold 27 433 shares of value $2 142 570 ), Rupert Vessey (Option Excercise at a value of $4 643 869), Rupert Vessey (Sold 142 205 shares of value $10 621 578 ), Samit Hirawat (Option Excercise at a value of $0), Sandra Leung (Option Excercise at a value of $0), Sharon Greenlees (Sold 0 shares of value $0 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (38.89 %)
7 (38.89 %)
7 (41.18 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
10 (55.56 %)
10 (55.56 %)
9 (52.94 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (5.56 %)
1 (5.56 %)
1 (5.88 %)
Summary RatingModerate Buy
2.29
Moderate Buy
2.29
Moderate Buy
2.25

Bristol-Myers Squibb Company

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

CEO: Giovanni Caforio

Telephone: +1 212 546-4000

Address: 430 E. 29th Street, New York 10016, NY, US

Number of employees: 30 250

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

51%49%

Bearish Bullish

55%45%

Bearish Bullish

54%46%

 

TipRanks News for BMY

Mon, 10 Jul 2023 10:45 GMT Bristol Myers (BMY) Has a New Rating from SVB Securities

- TipRanks. All rights reserved.

News

Stocktwits